Results 31 to 40 of about 1,173,119 (313)

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

open access: yesJournal of Market Access & Health Policy, 2018
Background: Market access stakeholders consider the adoption of Managed Entry Agreements (MEAs), however a clearly described methodology to quantify their implementation burden is not available in the public domain.
Panos Kefalas   +7 more
doaj   +1 more source

Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes

open access: yesMolecular Therapy: Methods & Clinical Development, 2018
The generation of clinical good manufacturing practices (GMP)-grade adeno-associated virus (AAV) vectors requires purification strategies that support the generation of vectors of high purity, and that exhibit a good safety and efficacy profile. To date,
Shelley A. Nass   +9 more
doaj   +1 more source

Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma

open access: yesScientific Reports, 2021
A promising therapy for patients with B-cell lymphoma is based on vaccination with idiotype monoclonal antibodies (mAbs). Since idiotypes are different in each tumor, a personalized vaccine has to be produced for each patient.
Erkuden Casales   +11 more
doaj   +1 more source

Evolutionary interplay between viruses and R‐loops

open access: yesFEBS Letters, EarlyView.
Viruses interact with specialized nucleic acid structures called R‐loops to influence host transcription, epigenetic states, latency, and immune evasion. This Perspective examines the roles of R‐loops in viral replication, integration, and silencing, and how viruses co‐opt or avoid these structures.
Zsolt Karányi   +4 more
wiley   +1 more source

Mesenchymal stem cell therapy for liver disease: full of chances and challenges

open access: yesCell & Bioscience, 2020
Liver disease is a major health problem that endangers human health worldwide. Currently, whole organ allograft transplantation is the gold standard for the treatment of end-stage liver disease.
Xue Yang   +5 more
doaj   +1 more source

Circulating histones as clinical biomarkers in critically ill conditions

open access: yesFEBS Letters, EarlyView.
Circulating histones are emerging as promising biomarkers in critical illness due to their diagnostic, prognostic, and therapeutic potential. Detection methods such as ELISA and mass spectrometry provide reliable approaches for quantifying histone levels in plasma samples.
José Luis García‐Gimenez   +17 more
wiley   +1 more source

Aurintricarboxylic acid increases yield of HSV-1 vectors

open access: yesMolecular Therapy: Methods & Clinical Development, 2014
Production of large quantities of viral vectors is crucial for the success of gene therapy in the clinic. There is a need for higher titers of herpes simplex virus-1 (HSV-1) vectors both for therapeutic use as well as in the manufacturing of clinical ...
Peter Pechan   +5 more
doaj   +1 more source

Gene therapy for hemophilia [PDF]

open access: yesJournal of Thrombosis and Haemostasis, 2013
Hemophilia A and B are X-linked monogenic disorders resulting from deficiencies of factor VIII and FIX, respectively. Purified clotting factor concentrates are currently intravenously administered to treat hemophilia, but this treatment is non-curative.
Thierry VandenDriessche   +3 more
openaire   +3 more sources

Single‐cell insights into the role of T cells in B‐cell malignancies

open access: yesFEBS Letters, EarlyView.
Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley   +1 more source

Autoimmune dysregulation and purine metabolism in adenosine deaminase (ADA)-deficiency

open access: yesFrontiers in Immunology, 2012
Genetic defects in the adenosine deaminase (ADA) gene are among the most common causes for severe combined immunodeficiency (SCID). ADA-SCID patients suffer from lymphopenia, severely impaired cellular and humoral immunity, failure to thrive and ...
Aisha Vanessa Sauer   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy